Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global portfolio
Some say it is "easy" to beat the S&P 500 this year. Tracey picked 5 random hot stocks to test the theory.
Eli Lilly (LLY) reachead $910.69 at the closing of the latest trading day, reflecting a -0.98% change compared to its last close.